

Sheet 1 of 8

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 21912-002009/1002H		Application No. 08/141,496	
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))				Applicant Marcus F. Boehm <i>et al.</i>			
				Filing Date October 22, 1993		Group Art Unit 1625	
<b>U.S. Patent Documents</b>							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/RD/	AA	4,002,631	01/11/77	Miyazawa et al.	546	116	07/24/74
	AB	4,025,552	05/24/77	Orzalesi	514	571	01/13/75
	AC	4,105,681	08/08/78	Bollaga et al.	554	111	08/13/76
	AD	4,193,931	03/18/80	Loeliger	514	510	04/24/78
	AE	4,215,215	07/29/80	Bollag et al.	544	176	07/06/79
	AF	4,272,547	06/09/81	Haas et al.	424	311	08/18/77
	AG	4,534,979	08/13/85	Loev et al.	514	529	11/02/84
	AH	4,539,154	09/03/85	Krebs	260	999.999	06/15/83
	AI	4,780,251	10/25/88	Aig et al.	554	220	10/23/86
	AJ	4,783,549	11/08/88	Lang et al.	560	104	09/04/85
	AK	4,833,240	05/23/89	Maignan et al.	536	55.2	07/17/87
	AL	4,833,254	05/23/89	Berlin et al.	548	454	05/11/87
	AM	4,879,284	11/07/89	Land et al.	514	237.5	12/05/86
	AN	4,892,940	01/09/90	Maignan et al.	536	58	05/22/87
	AO	4,898,864	02/06/90	Maignan et al.	514	237.5	10/27/87
	AP	4,977,276	12/11/90	Berlin et al.	549	52	12/28/89
	AQ	5,149,705	09/22/92	Chandraratna	514	356	03/13/87
	AR	5,192,534	03/09/93	Grollier et al.	424	59	02/13/92
	AS	5,198,567	03/30/93	Lang et al.	560	56	07/23/91
	AT	5,219,888	06/15/93	Katocs Jr. et al.	514	560	03/31/92
	AU	5,272,146	12/21/93	Haugwitz et al.	514	232.8	10/02/92
	AV	5,304,575	04/19/94	Beck	514	563	12/17/92
	AW	5,391,766	02/21/95	Klaus et al.	549	23	05/05/93
	AX	5,428,071	06/27/95	Bollag et al.	514	559	02/24/84
	AY	5,455,265	10/03/95	Chandraratna	514	448	02/11/93
	AZ	5,466,861	11/14/95	Dawson et al.	560	100	11/25/92
/RD/	BA	5,508,456	04/16/96	Boehm	554	163	05/27/94
Examiner Signature /Rita Desai/				Date Considered 11/13/2007			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21912-002009/1002H	Application No. 08/141,496
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))		Applicant Marcus F. Boehm <i>et al.</i>	
		Filing Date October 22, 1993	Group Art Unit 1625

## U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/RD/	BB	5,514,821	05/07/96	Bennani et al.	554	221	05/27/94
	BC	5,552,271	09/03/96	Pfahl et al.	435	6	11/25/92
	BD	5,567,855	10/22/96	White et al.	568	449	04/21/94
	BE	5,721,103	02/24/98	Boehm et al.	435	7.1	06/07/95
	BF	5,770,378	06/23/98	Hwang et al.	435	7.1	06/07/95
	BG	5,770,382	06/23/98	Hwang et al.	435	7.1	06/07/95
	BH	5,770,383	06/23/98	Hwang et al.	435	7.1	06/07/95
	BI	5,780,676	07/14/98	Boehm et al.	562	490	06/07/95
	BJ	5,837,725	11/17/98	Dawson et al.	514	467	05/24/95
	BK	5,932,622	08/03/99	Evans et al.	514	725	06/07/95
	BL	5,962,731	10/02/99	Boehm et al.	562	460	06/07/95
	BM	5,968,989	10/19/99	Evans et al.	514	725	06/07/95
	BN	5,998,654	12/07/99	Boehm et al.	560	45	07/25/97
	BO	6,028,052	02/22/00	Heyman et al.	514	3	09/17/96
	BP	6,043,279	03/28/00	Boehm et al.	514	568	02/12/97
	BQ	6,083,977	07/04/00	Boehm et al.	514	457	06/07/95
	BR	6,576,676	06/10/03	Evans et al.	514	725	07/09/99
/RD/	BS	6,610,883	08/26/03	Boehm et al.	562	490	07/13/98

## Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/RD/	BT	0284288	09/28/88	EP				
	BU	03/007950	01/30/03	PCT				
	BV	1526410	09/27/78	UK				
	BW	2188634	10/07/87	UK				
	BX	2293193	07/02/76	FR				X+
/RD/	BY	2505106	08/21/75	DE				X+

Examiner Signature  /Rita Desai/	Date Considered  11/13/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21912-002009/1002H	Application No. 08/141,496
	Applicant Marcus F. Boehm <i>et al.</i>		
	Filing Date October 22, 1993	Group Art Unit 1625	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/RD/	BZ	253393	01/20/88	EP				
	CA	2601670	01/22/88	FR				X+
	CB	266992	05/11/88	EP				
	CC	93/11755	06/24/93	PCT				
	CD	93/15740	08/19/93	PCT				
/RD/	CE	93/21146	10/28/93	PCT				

X+ = An English language equivalent is provided.

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
/RD/	CF	Allegretto et al., "Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism," J Biol Chem. 268(35):26625-33 (1993). Erratum in: J Biol Chem 269(10):7834 (1994)
	CG	Bisagni et al., "Partially hydrogenated derivatives of 7,12-dimethylbenz[a]anthracene. II. Different routes to 2-(1',2',3',4'-tetrahydro-5',8'-dimethyl-6'-naphthyl)cyclohexanone and syntheses of various other intermediates," Bulletin de la Societe Chimique de France, 8-9:3031-3038, (1970).
	CH	Boehm et al., "Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells," J Med Chem. 38(16):3146-3155 (1995)
	CI	Boehm et al. "Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids," Journal of Medicinal Chemistry 37(18):2930-2941 (1994)
	CJ	Boehm et al., "Synthesis of high specific activity [ <sup>3</sup> H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties," J Med Chem. 37(3):408-14 (1994)
	CK	Burnham Report, "Unlocking the mysteries of cells to improve human life," 1(1), Winter, (2003).
	CL	Certified English translation of: Bisagni et al., "Partially hydrogenated derivatives of 7,12-dimethylbenz[a]anthracene. II. Different routes to 2-(1',2',3',4'-tetrahydro-5',8'-dimethyl-6'-naphthyl)cyclohexanone and syntheses of various other intermediates," Bulletin de la Societe Chimique de France, 8-9:3031-3038, (1970).
	CM	Damm et al., "Functional inhibition of retinoic acid response by dominant negative retinoic acid receptor mutants," Proc Natl Acad Sci U S A. 90(7):2989-2993 (1993)
	CN	Dawson, "Synthetic retinoids and their nuclear receptors," Curr Med Chem Anticancer Agents, 4(3):199-230 (2004)
	CO	Dawson and Zhang, "Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid," Curr Med Chem., 9(6):623-637 (2002)
	CP	Faisst et al., "Compilation of vertebrate-encoded transcription factors," Nucleic Acids Reseach 20(1):3-26 (1992)
/RD/	CQ	Freshney, "Culture of Animal Cells, A Manual of Basic Technique", Alan R. Liss, Inc., New York, p4 (1983)

Examiner Signature  /Rita Desai/	Date Considered  11/13/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 21912-002009/1002H	Application No. 08/141,496
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))				Applicant Marcus F. Boehm <i>et al.</i>	
				Filing Date October 22, 1993	Group Art Unit 1625
Other Documents (include Author, Title, Date, and Place of Publication)					
Examiner Initial	Desig. ID	Document			
/RD/	CR	Graupner et al., "6'-substituted naphthalene-3-carboxylic acid analogs, a new class of retinoic acid receptor subtype-specific ligands," Biochemical and Biophysical Research Communications 179(3):1554-1561 (1991)			
	CS	Gupta, et al., "Synthesis of polynuclear hydrocarbons with fused cyclopentane ring. II," Journal of the Indian Chemical Society, 30:805-808, (1954).			
	CT	Hashimoto et al., "Expression of retinoic acid receptor genes and the ligand-binding selectivity of retinoic acid receptors," Chemical Abstracts 112(15): Abstract No. 136342b (1990)			
	CU	Jones, B.A. and J.S. Bradshaw, "Synthesis and Reduction of Thiocarboxylic O-Esters," Chem. Rev. 84:17-30 (1984)			
	CV	Kliwer et al., "Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling," Proc Natl Acad Sci U S A. 89(4):1448-1452 (1992)			
	CW	Loeliger et al., "Arotinoids, a new class of highly active retinoids," European J. of Medicinal Chemistry 15(1):9-15 (1980)			
	CX	Lotan, R. "Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells," Biochimica et Biophysica Acta, 605: 33-91 (1980)			
	CY	Mangelsdorf et al., "Characterization of three RXR genes that mediate the action of 9-cis retinoic acid," Genes Dev. 6(3):329-344 (1992)			
	CZ	Nadzan, A.M., "Chapter 13. Retinoids for the treatment of oncological diseases," Annual Reports in Medicinal Chemistry, 30: 119-128 (1995)			
	DA	Nadzan et al., "Design of novel RXR selective retinoids," European Journal of Medicinal Chemistry, 30(Suppl.):519s-533s (1995)			
	DB	Press Release 01/26/05: "Ligand Provides Update and Answers to Frequently Asked Questions on the Status of SPIRIT I & II Pivotal Studies of Targretin Capsules in Non-Small Cell Lung Cancer," <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=667166">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=667166</a> (accessed on 04/08/05)			
	DC	Press Release 03/14/05: "Ligand and SRI/Burnham Agree to Settle Patent Interference on Targretin; Ligand Strengthens Targretin Patent Protection and Lowers Royalty Rate," <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=684924">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=684924</a> (accessed on 04/08/05)			
	DD	Press Release 03/28/05: "Targretin Fails to Meet Primary or Secondary Endpoints in Pivotal Trials for Front-Line Non-Small Cell Lung Cancer," <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=689144">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=689144</a> (accessed on 04/08/05)			
	DE	Press Release 03/31/04: "Ligand Updates SPIRIT I and II Pivotal Studies of Targretin Capsules in Lung Cancer; Final Statistical Plan Agreed With FDA Shifts Survival Data Availability for Both Studies to 1Q05," <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=460&amp;layout=-6&amp;item_id=510199">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=460&amp;layout=-6&amp;item_id=510199</a> (accessed on 04/08/05)			
/RD/	DF	Press Release 06/07/04: "Ligand and Investigators Present Exciting Scientific and Clinical Data Updates for Oncology Products Targretin and ONTAK at ASCO Meeting," <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=579100">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGND&amp;script=410&amp;layout=-6&amp;item_id=579100</a> (accessed on 04/08/05)			

Examiner Signature

/Rita Desai/

Date Considered

11/13/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21912-002009/1002H	Application No. 08/141,496
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))			Applicant Marcus F. Boehm <i>et al.</i>	
			Filing Date October 22, 1993	Group Art Unit 1625
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
/RD/	DG	Press Release 03/29/04: "New Findings Presented at AACR Show Ligand's Targretin Synergizes with Chemotherapeutic Agents to Arrest NSCLC Growth and Prevents or Reverses Acquired Paclitaxel and Taxol Resistance in NSCLC and Advanced Breast Cancer," <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=509239">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=509239</a> (accessed on 04/08/05)		
	DH	Press Release 09/18/03: Ligand Completes Patient Enrollment in Second Pivotal Study of Targretin Capsules in Lung Cancer One Quarter Ahead of Schedule <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=450284">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=450284</a> (accessed on 04/08/05)		
	DI	Press Release 08/14/03: Ligand Completes Patient Enrollment in First Pivotal Study of Targretin-R-Capsules in Lung Cancer Ahead of Schedule <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=441327">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=441327</a> (accessed on 04/08/05)		
	DJ	Press Release 04/08/03: Ligand's Targretin Combined With Taxol Prevents and Overcomes Acquired Taxol Resistance in Vitro and in Vivo, Preclinical Breast Cancer Studies Demonstrate <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=399343">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=399343</a> (accessed on 04/08/05)		
	DK	Press Release 03/24/03: Four Clinical Trials Presented at AAD Show Ligand's Targretin, Panretin Demonstrate Promising Activity in Range of Dermatologic Disorders <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=393903">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=393903</a> (accessed on 04/08/05)		
	DL	Press Release 02/20/03: Ligand's Targretin Gel Shows Promise for Chronic Severe Hand Dermatitis Patients <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=384737">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=384737</a> (accessed on 04/08/05)		
	DM	Press Release 12/09/02: Ligand's Targretin Prevents Development of Mammary Tumors in Pre-Clinical Study of ER-Negative Breast Cancer, Journal Article Reports <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=362558">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=362558</a> (accessed on 04/08/05)		
	DN	Press Release 09/05/02: Ligand's Targretin Gel Shows Promise for Many Chronic Severe Hand Dermatitis Patients <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=331693">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=331693</a> (accessed on 04/08/05)		
	DO	Press Release 08/29/02: Targretin Increases Susceptibility of Leukemic B- and T-Cells to ONTAK, In Vitro Study of Ligand Products Published in the Journal Blood Demonstrates <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=330013">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=330013</a> (accessed on 04/08/05)		
/RD/	DP	Press Release 05/20/02: Clinical Studies of Targretin Capsules and ONTAK Presented at ASCO Underscore Potential of Ligand Drugs to Treat Lung Cancer, Chronic Lymphocytic Leukemia <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=298548">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=298548</a> (accessed on 04/08/05)		

Examiner Signature  /Rita Desai/	Date Considered  11/13/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21912-002009/1002H	Application No. 08/141,496
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))			Applicant Marcus F. Boehm <i>et al.</i>	
			Filing Date October 22, 1993	Group Art Unit 1625
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
/RD/	DQ	Press Release 05/17/02: Treatment With Targretin-R- -Bexarotene- Reduces Cell Proliferation in Psoriatic Skin, One of Several Ligand-Related Studies Presented at SID Demonstrates <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=297850">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=297850</a> (accessed on 04/08/05)		
	DR	Press Release 02/28/02: Targretin Gel Achieved 86% Response Rate in Early-Stage CTCL Patients Treated for More Than One Year, Researchers Report At AAD Meeting <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=264329">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=264329</a> (accessed on 04/08/05)		
	DS	Press Release 12/11/01: Highlights from Nine Ligand-Related Abstracts at American Society of Hematology Meeting <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=235532">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=235532</a> (accessed on 04/08/05)		
	DT	Press Release 10/30/01: Ligand Pharmaceuticals Recognized by Cure for Lymphoma Foundation for Contributions to Lymphoma Education, Research and Treatment <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=221914">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=221914</a> (accessed on 04/08/05)		
	DU	Press Release 05/15/01: Targretin Capsules in Combination Therapy May Prolong Survival in Patients with Non-Small Cell Lung Cancer; Data from Phase I-II Trials Published in The Journal of Clinical Oncology <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=176069">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=176069</a> (accessed on 04/08/05)		
	DV	Press Release 05/14/01: Targretin Capsules May Improve Survival in Patients with Advanced Renal Cell Cancer; Combination Therapy May Delay Disease Progression <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=175607">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=175607</a> (accessed on 04/08/05)		
	DW	Press Release 03/19/01: Ligand Provides Targretin Registration/Clinical Data Update in Non-Small Cell Lung Cancer, Breast Cancer and Psoriasis <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=159844">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=159844</a> (accessed on 04/08/05)		
	DX	Press Release 12/05/00: Ligand's ONTAK in Combination With Steroids Doubled Overall Response Rate In CTCL; Three Posters on ONTAK and Targretin at American Society of Hematology Meeting <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=136953">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=136953</a> (accessed on 04/08/05)		
	DY	Press Release 11/20/00: Ligand's Targretin Capsules Recommended for Approval by European CPMP; Second Product for Ligand Europe Commercialization <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=134039">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=134039</a> (accessed on 04/08/05)		
/RD/	DZ	Press Release 11/08/00: Ligand's Targretin May Extend Survival in Lung Cancer Patients; Data Reported at the NCI-EORTC-AACR Meeting <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130921">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130921</a> (accessed on 04/08/05)		

Examiner Signature  /Rita Desai/	Date Considered 11/13/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21912-002009/1002H	Application No. 08/141,496
<b>List of Patents and Publications for Applicant's Information Disclosure Statement</b>  (37 CFR §1.98(b))		Applicant <b>Marcus F. Boehm <i>et al.</i></b>	
		Filing Date <b>October 22, 1993</b>	Group Art Unit <b>1625</b>
<b>Other Documents (include Author, Title, Date, and Place of Publication)</b>			
Examiner Initial	Desig. ID	Document	
/RD/	EA	Press Release 08/29/00: Data Suggest Targretin Capsules May Improve Effectiveness of ONTAK Through Upregulation of IL-2 Receptor <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130865">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130865</a> (accessed on 04/08/05)	
	EB	Press Release 08/14/00: Targretin--R-- Capsules May Increase Survival in Patients with Non-Small Cell Lung Cancer; Follow-Up Results of Clinical Studies Support FDA Dialogue/Phase III Program <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130859">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130859</a> (accessed on 04/08/05)	
	EC	Press Release 06/29/00: Ligand Receives FDA Marketing Clearance for Targretin Gel; Approval Adds Fourth Product to Ligand's Specialty Oncology Products Business <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130843">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130843</a> (accessed on 04/08/05)	
	ED	Press Release 06/12/00: Ligand Receives Approvable Letter from FDA for Targretin Gel; Approval Would Mark Fourth Product Approval for Ligand in Past 18 Months <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130842">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130842</a> (accessed on 04/08/05)	
	EE	Press Release 05/23/00: Targretin Capsules Shows Activity in Clinical Trials in Patients with Non-Small Cell Lung Cancer and Cutaneous T-Cell Lymphoma <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130837">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130837</a> (accessed on 04/08/05)	
	EF	Press Release 05/09/00: Clinical Trial Results of Targretin(R) Gel in Early-Stage CTCL To Be Presented at SID Annual Meeting <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130793">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130793</a> (accessed on 04/08/05)	
	EG	Press Release 05/03/00: Targretin(R) Capsules Show Positive Results in Moderate to Severe Plaque Psoriasis; Targretin Capsules Also Effective in Treating All Stages Of CTCL <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130792">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130792</a> (accessed on 04/08/05)	
	EH	Press Release 03/13/00: Targretin Capsules Benefit Patients with All Stages of Cutaneous T-Cell Lymphoma; Results of Phase III Trials Presented at American Academy of Dermatology Meeting <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130790">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130790</a> (accessed on 04/08/05)	
	EI	Press Release 03/09/00: Ligand Reports 1999 Results; Ends Year With Three FDA Product Approvals and Cash of \$49.2 Million <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130788">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130788</a> (accessed on 04/08/05)	
	EJ	Press Release 02/18/00: Ligand Presents Data on Novel RXR Homodimer Antagonist Compound with Potential Utility in Diabetes and Obesity <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130786">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130786</a> (accessed on 04/08/05)	
/RD/	EK	Press Release 02/07/00: FDA Grants Priority Review for Ligand's Targretin Gel NDA <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130784">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130784</a> (accessed on 04/08/05)	
Examiner Signature  <div style="text-align: center; font-size: 1.2em;">/Rita Desai/</div>		Date Considered  <div style="text-align: center; font-size: 1.2em;">11/13/2007</div>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 21912-002009/1002H	Application No. 08/141,496
List of Patents and Publications for Applicant's Information Disclosure Statement  (37 CFR §1.98(b))			Applicant Marcus F. Boehm <i>et al.</i>	
			Filing Date October 22, 1993	Group Art Unit 1625
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
/RD/	EL	Press Release 01/06/00: Ligand and Alfa Wassermann Enter Into Marketing and Distribution Agreement for Italy for Ontak, Targretin and Panretin <a href="http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130779">http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=LGNDE&amp;script=460&amp;layout=-6&amp;item_id=130779</a> (accessed on 04/08/05)		
	EM	Rakto et al., "Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in femal rats," Cancer Res. 49(16):4472-4476 (1989)		
	EN	Sofina et al., "Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations", NCL Monograph 55, NIH Publication No. 80-1933, pp 76-78 (1980)		
	EO	Spruce et al., "Heteroarotinoids. Synthesis, Characterization, and Biological Activity in Terms of an Assessment of These Systems To Inhibit the Induction of Ornithine Decarboxylase Activity and To Induce Terminal Differentiation of HL-60 Cells," J. Med. Chem. 30: 1474-1482 (1987)		
	EP	Strandtmann et al., "Reaction of Cyclic beta-diketones with 3,4-Dihydroisoquinolines and Related Compounds. Preparation and Anticancer Activity of 2-Substituted 1,3-Cyclohexanediones", J. Med. Chem. 10(6):1063-1065 (1967).		
	EQ	van der Leede et al., "Retinoic Acid Receptor and Retinoid X Receptor Expression in Retinoic Acid-Resistant Human Tumor Cell Lines," Molecular Carcinogenesis. 8:112-122 (1993).		
/RD/	ER	Zhang et al., "Discovery of Novel Retinoic Acid Receptor Agonists Having Potent Antiproliferative Activity in Cervical Cancer Cells", J. Med. Chem. 39(14):2659-2663 (1996).		

Examiner Signature /Rita Desai/	Date Considered 11/13/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	